Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ADALIMUMAB Cause Infection susceptibility increased? 179 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 179 reports of Infection susceptibility increased have been filed in association with ADALIMUMAB (YUSIMRY). This represents 0.0% of all adverse event reports for ADALIMUMAB.

179
Reports of Infection susceptibility increased with ADALIMUMAB
0.0%
of all ADALIMUMAB reports
3
Deaths
69
Hospitalizations

How Dangerous Is Infection susceptibility increased From ADALIMUMAB?

Of the 179 reports, 3 (1.7%) resulted in death, 69 (38.5%) required hospitalization, and 1 (0.6%) were considered life-threatening.

Is Infection susceptibility increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ADALIMUMAB. However, 179 reports have been filed with the FAERS database.

What Other Side Effects Does ADALIMUMAB Cause?

Drug ineffective (71,926) Pain (37,514) Arthralgia (35,592) Rheumatoid arthritis (29,817) Fatigue (29,420) Injection site pain (28,679) Headache (19,891) Nausea (19,299) Rash (18,690) Pain in extremity (18,319)

What Other Drugs Cause Infection susceptibility increased?

ETANERCEPT (160) OCRELIZUMAB (118) METHOTREXATE (95) PREDNISONE (67) DIMETHYL (64) MYCOPHENOLATE MOFETIL (64) PREDNISOLONE (62) SECUKINUMAB (59) TOFACITINIB (57) APREMILAST (53)

Which ADALIMUMAB Alternatives Have Lower Infection susceptibility increased Risk?

ADALIMUMAB vs ADALIMUMAB-AACF ADALIMUMAB vs ADALIMUMAB-AATY ADALIMUMAB vs ADALIMUMAB-ADAZ ADALIMUMAB vs ADALIMUMAB-ADBM ADALIMUMAB vs ADALIMUMAB-AFZB

Related Pages

ADALIMUMAB Full Profile All Infection susceptibility increased Reports All Drugs Causing Infection susceptibility increased ADALIMUMAB Demographics